[go: up one dir, main page]

RU2000116260A - LTB ADJUVANT VACCINES - Google Patents

LTB ADJUVANT VACCINES

Info

Publication number
RU2000116260A
RU2000116260A RU2000116260/14A RU2000116260A RU2000116260A RU 2000116260 A RU2000116260 A RU 2000116260A RU 2000116260/14 A RU2000116260/14 A RU 2000116260/14A RU 2000116260 A RU2000116260 A RU 2000116260A RU 2000116260 A RU2000116260 A RU 2000116260A
Authority
RU
Russia
Prior art keywords
immunogen
subunits
ltb
mucous membranes
holotoxin
Prior art date
Application number
RU2000116260/14A
Other languages
Russian (ru)
Other versions
RU2211050C2 (en
Inventor
Этьен АГСТЕРИББ
Руди БРАНДС
ХАН Лольке ДЕ
СХАРРЕНБУРГ Гюстаф Йохан Мари ВАН
Виллем Рональд ВЕРВЕЙ
Ян Христиан ВИЛЬСХУТ
Original Assignee
Дюфар Интернэшнл Рисерч Б.В.
Университет Ван Гронинген
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97203671A external-priority patent/EP0919243A1/en
Application filed by Дюфар Интернэшнл Рисерч Б.В., Университет Ван Гронинген filed Critical Дюфар Интернэшнл Рисерч Б.В.
Publication of RU2000116260A publication Critical patent/RU2000116260A/en
Application granted granted Critical
Publication of RU2211050C2 publication Critical patent/RU2211050C2/en

Links

Claims (9)

1. Вакцина для введения на слизистые оболочки, содержащая по меньшей мере один корпускулярный иммуноген и адъювантное количество субъединиц В термолабильного энтеротоксина (LTB), характерного для Е. coli, совершенно не содержащее субъединиц А или токсического LT голотоксина.1. A vaccine for administration to the mucous membranes containing at least one corpuscular immunogen and an adjuvant number of B thermolabile enterotoxin (LTB), characteristic of E. coli, completely free of A subunits or toxic LT holotoxin. 2. Вакцина по п. 1, в которой LTB получают с помощью методик рекомбинантных ДНК. 2. The vaccine according to claim 1, in which LTB is obtained using recombinant DNA techniques. 3. Вакцина по пп. 1 и 2, в которой в качестве иммуногена используются вирусные или бактериальные или грибковые антигены. 3. The vaccine according to paragraphs. 1 and 2, in which viral or bacterial or fungal antigens are used as an immunogen. 4. Вакцина по пп. 1-3, в которой иммуноген обеспечивает иммунизанию против заболевания, которое передается инфекцией слизистых оболочек. 4. The vaccine according to paragraphs. 1-3, in which the immunogen provides immunization against a disease that is transmitted by an infection of the mucous membranes. 5. Вакцина по п. 4, в которой в качестве иммуногена используются антигены вируса гриппа. 5. The vaccine according to claim 4, in which influenza antigens are used as an immunogen. 6. Способ индукции системного иммуноглобулинового ответа на иммуноген путем введения на слизистые оболочки указанного иммуногена в корпускулярной форме и адъювантного количества субъединиц В термолабильного энтеротоксина, характерного для Е. coli, совершенно не содержащего субъединиц А или токсического LT голотоксина. 6. A method for inducing a systemic immunoglobulin response to an immunogen by administering to the mucous membranes of the indicated immunogen in particulate form and an adjuvant amount of B thermolabile enterotoxin characteristic of E. coli, completely free of A subunits or toxic LT holotoxin. 7. Способ индукции общего иммунного ответа слизистых оболочек на иммуноген путем введения на слизистые оболочки указанного иммуногена в корпускулярной форме и адъювантного количества субъединиц В термолабильного энтеротоксина, характерного для Е. coli, совершенно не содержащего субъединиц А или токсического LT голотоксина. 7. A method for inducing the general immune response of mucous membranes to an immunogen by administering to the mucous membranes of the indicated immunogen in corpuscular form and an adjuvant amount of B thermolabile enterotoxin, characteristic of E. coli, completely free of A subunits or toxic LT holotoxin. 8. Применение субъединиц В термолабильного энтеротоксина (LTB), характерного для Е. coli, совершенно не содержащего субъединиц А или токсического LT голотоксина, в изготовлении вакцины, включающей корпускулярный иммуноген и адъювантное количество указанного LTB, подходящей для индукции системного иммуноглобулинового ответа на указанный иммуноген у индивидуума после введения на слизистые оболочки. 8. The use of the B subunits of the thermolabile enterotoxin (LTB) characteristic of E. coli, completely free of subunits A or toxic LT holotoxin, in the manufacture of a vaccine comprising a corpuscular immunogen and an adjuvant amount of said LTB suitable for inducing a systemic immunoglobulin response to the specified immunogen in an individual after administration to the mucous membranes. 9. Применение субъединиц В термолабильного энтеротоксина (LTB), характерного для Е. coli, совершенно не содержащего субъединиц А или токсического LT голотоксина, в изготовлении вакцины, включающей корпускулярный иммуноген и адъювантное количество указанного LTB, подходящей для индукции общего иммунного ответа слизистых оболочек на указанный иммуноген у индивидуума после локального введения на слизистые оболочки. 9. Use of the thermolabile enterotoxin (LTB) subunits B characteristic of E. coli, completely free of A subunits or toxic holotoxin LT, in the manufacture of a vaccine comprising a corpuscular immunogen and an adjuvant amount of said LTB suitable for inducing a general mucosal immune response to said immunogen in an individual after local administration to mucous membranes.
RU2000116260/14A 1997-11-25 1998-11-24 Vaccines with ltb adjuvant RU2211050C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203671.9 1997-11-25
EP97203671A EP0919243A1 (en) 1997-11-25 1997-11-25 Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant

Publications (2)

Publication Number Publication Date
RU2000116260A true RU2000116260A (en) 2002-06-27
RU2211050C2 RU2211050C2 (en) 2003-08-27

Family

ID=8228966

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000116260/14A RU2211050C2 (en) 1997-11-25 1998-11-24 Vaccines with ltb adjuvant

Country Status (25)

Country Link
US (1) US6793928B1 (en)
EP (2) EP0919243A1 (en)
JP (1) JP4235359B2 (en)
KR (1) KR100575019B1 (en)
CN (1) CN1227032C (en)
AT (1) ATE238809T1 (en)
AU (1) AU747061C (en)
BR (1) BR9815413A (en)
CA (1) CA2311492C (en)
CZ (1) CZ299770B6 (en)
DE (1) DE69814177T2 (en)
DK (1) DK1071456T3 (en)
ES (1) ES2198089T3 (en)
HK (1) HK1031102A1 (en)
HU (1) HU226214B1 (en)
IL (2) IL135905A0 (en)
NO (1) NO324690B1 (en)
NZ (1) NZ504396A (en)
PL (1) PL190925B1 (en)
PT (1) PT1071456E (en)
RU (1) RU2211050C2 (en)
SK (1) SK284572B6 (en)
TR (1) TR200001485T2 (en)
UA (1) UA72199C2 (en)
WO (1) WO1999026654A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2473691C2 (en) * 2006-10-12 2013-01-27 Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа Fused protein of telomerase reverse transcriptase, nucleotides coding them, and using them

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
NZ507911A (en) * 1998-05-08 2004-04-30 Univ Bristol Immunomodulators for vaccines
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
AU2003261492B2 (en) * 1998-05-08 2006-09-07 Trident Pharmaceuticals, Inc. Vaccine
JP4889175B2 (en) * 1999-10-18 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Compositions and methods for stimulating an immune response against infectious agents
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
US20060002960A1 (en) * 2003-12-09 2006-01-05 Paul Zoeteweij GM1 binding deficient exotoxins for use as immunoadjuvants
JP5028627B2 (en) 2005-08-05 2012-09-19 国立大学法人徳島大学 Antigen drug vehicle that enables switching from selective production of IgA antibody to production of both IgA and IgG antibodies, and nasal / mucosal vaccine using the same
TWI397419B (en) * 2006-03-22 2013-06-01 Abbott Biologicals Bv Intranasal or inhalational administration of virosomes
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP3058954B1 (en) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2535428B1 (en) 2007-10-01 2015-09-09 Longhorn Vaccines and Diagnostics, LLC Biological specimen collection and transport system and methods of use
KR101887040B1 (en) * 2012-06-20 2018-08-09 고쿠리츠다이가쿠호징 도쿄다이가쿠 Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection
CN106170551B (en) 2013-12-16 2020-01-07 财团法人农业科技研究院 Plasmids, methods and kits for producing thermolabile enterotoxin B subunits
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
WO2019089410A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
CA3087569A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
CA3094174A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
CN113616783A (en) * 2020-05-08 2021-11-09 昱厚生技股份有限公司 Methods of preventing or treating coronavirus infection using immunomodulators and vaccine compositions comprising the immunomodulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (en) 1974-01-14 1977-07-15 Sandoz Ag
JP2849632B2 (en) * 1988-04-08 1999-01-20 社団法人北里研究所 Vaccine preparation
CA2004738A1 (en) * 1988-12-07 1990-06-07 University Of Leicester Heat-labile toxin b subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2473691C2 (en) * 2006-10-12 2013-01-27 Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа Fused protein of telomerase reverse transcriptase, nucleotides coding them, and using them

Similar Documents

Publication Publication Date Title
RU2000116260A (en) LTB ADJUVANT VACCINES
US5026543A (en) Adjuvant mixture
Tochikubo et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin
CA2311492A1 (en) Vaccines with an ltb adjuvant
JP4484904B2 (en) Immunization by inoculation with DNA transcription unit
ES2257072T3 (en) ANTIGRIPAL VACCINE COMPOSITION.
JP2001523729A5 (en)
FI955667A0 (en) Adjuvants for RS virus vaccines
Golovliov et al. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis
RU95122391A (en) ADJUVENTS FOR VACCINE AGAINST RESPIRATORY-SYNCITIAL VIRUS
RU98101249A (en) OMR26 ANTIGEN HAEMOPHYLUS INFLUENZAE
NO301577B1 (en) Method for Preparing a Stable Vaccine Mix and Method for Stabilizing Interleukin in a Vaccine Mix
Sasaki et al. Adjuvant effect of Ubenimex on a DNA vaccine for HIV‐1
KR20030015288A (en) Qs-21 and il-12 as an adjuvant combination
US5565209A (en) Adjuvant mixture
Ben Ahmeida et al. The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus
CA2114611A1 (en) Method of reversing immunosuppression in vaccines
KR920004422A (en) Major Neutralizing Determinants of HIV
GB1441098A (en) Biological preparations
WO1998001558A3 (en) Protein and peptide vaccines for inducing mucosal immunity
WO1999008689A1 (en) Mucosal immunization using particle-mediated delivery techniques
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
KR960705919A (en) Vaccine AGAINST MUMPS CONTAINING A JERYL-LYNN VIRUS STRAIN Containing JERYL-LYNN Virus Strain
WO2002053183A1 (en) Hantavirus vaccin with adjuvant